Forte Biosciences, Inc. (NASDAQ: FBRX) had its price target raised by analysts at Chardan Capital from $3.00 to $64.00. They now have a "buy" rating on the stock.
NeutralReport
Forte Biosciences, Inc. (NASDAQ: FBRX) had its price target raised by analysts at Chardan Capital from $3.00 to $64.00. They now have a "buy" rating on the stock.
Forte Biosciences, Inc. (NASDAQ: FBRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
MediumReport
Forte Biosciences, Inc. (NASDAQ: FBRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: